Transthyretin cardiac amyloidosis in Saudi Arabia and the Middle East: insights, projected prevalence and practical applications

Front Cardiovasc Med. 2023 Oct 25:10:1265681. doi: 10.3389/fcvm.2023.1265681. eCollection 2023.

Dania Mohty^#^{1

2}, Mohamed H Omer^#³, Omar Ahmad², Islam Alayary⁴, Talal Alzahrani⁵, Thibaud Damy⁶, Bahaa Fadel^{1

2}

¹ Heart Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
² College of Medicine, Al Faisal University, Riyadh, Saudi Arabia.
³ School of Medicine, Cardiff University, Cardiff, United Kingdom.
⁴ Rare Diseases Medical Affairs, Pfizer Inc., Jeddah, Saudi Arabia.
⁵ Department of Medicine, College of Medicine, Taibah University, Medina, Saudi Arabia.
⁶ Referral Center for Cardiac Amyloidosis, Department of Cardiology, Mondor Amyloidosis Network, GRC Amyloid Research Institute, Clinical Investigation Center 006, DHU A-TVB INSERM U955 all at CHU Henri Mondor, UPEC, Créteil, France.

^# Contributed equally.

No abstract available

Keywords: Middle East; Saudi Arabia; cardiac amyloidosis; epidemiology; incidence; prevalence; transthyretin.

Grants and funding

The authors declare financial support was received for the research, authorship, and/or publication of this article.